Neoplasms Clinical Trials

A listing of 58 Neoplasms clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Neoplasms

13 - 24 of 58

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 58 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Neoplasms participants are California, Texas, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157

Recruiting

The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: City of Hope, Duarte, California +21 locations

Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis

Learn More ›

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

Recruiting

Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN. Objective: To test a new treatment (TNh... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

07/10/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms

Learn More ›

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626

Recruiting

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Loma Linda University Cancer Center, Loma Linda, California +31 locations

Loma Linda University Cancer Center, Loma Linda, California

UC Davis Comprehensive Cancer Center, Sacramento, California

Sarah Cannon Research Institute at HealthONE, Denver, Colorado

AdventHealth Celebration, Celebration, Florida

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

The University of Kansas Cancer Center, Kansas City, Kansas

National Institutes of Health, Bethesda, Maryland

Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Memorial Sloan-Kettering Cancer Center, New York, New York

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, Oklahoma

Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville, Tennessee

The University of Texas, MD Anderson Cancer Center, Houston, Texas

UT Health Mays Cancer Center, San Antonio, Texas

Fred Hutchinson Cancer Center, Seattle, Washington

University of Wisconsin- Madison, Madison, Wisconsin

Princess Margaret Cancer Centre, Toronto, Ontario

Research Institute of McGill University Health Centre, Montreal, Quebec

Institut Bergonié, Bordeaux, Not set

Centre Leon Berard, Lyon, Not set

Hopsital Institut Curie, Paris, Not set

Oncopole Claudius Regaud IUCT, Toulouse, Not set

Institute Gustave Roussy, Villejuif, Not set

Vall d'Hebron Institute of Oncology, Barcelona, Cataluna

Clinica Universidad de Navarra, San Blas-Canillejas, Madrid

NEXT Oncology Barcelona, Hospital Quirónsalud Barcelona, Barcelona, Not set

START Madrid FJD, Madrid, Not set

Hospital Universitario Quirónsalud Madrid, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Instituto de Investigacion Sanitaria, INCLIVA, Valencia, Not set

Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm

Learn More ›

Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue

NCT06482515

Recruiting

Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation). It is not relieved by sleep or rest, and it sometimes can persist for years after a person's cancer was treated. The fatigue can be so bad that people cannot return to work, hobbies, family roles, or other daily activities, thereby greatly reducing quality of life. The causes of this fatigue are unknown, and we currently do not have anything that can reliably prevent or cure the fatigue. However, there are recent data suggesting that circadian rhythm, or a person's internal body clock, may be disrupted by the cancer experience and contribute to fatigue. Food intake is an external cue that can entrain circadian rhythm. We recently showed that cancer survivors are willing and able to eat all their food within a 10-hour eating window-a practice called time-restricted eating. Herein, we are testing time-restricted eating against a control group (matched for time-, attention, and expectancy) to see if time-restricted eating can indeed alleviate cancer-related fatigue. All participants will be asked to use the myCircadianClock smartphone app to log their food intake and weekly body weight measurements. The participants assigned to the time-restricted eating group will be asked to eat all their food in a 10-hour window during the day. People can choose their start time based on their schedule and preferences, but we ask that the window is the same for the whole study (e.g., 7am-5pm,9:30am-7:30pm). Black coffee and unsweetened tea are allowed before the eating window, and water and medicines are allowed at all times. The participants in the control group will meet with a nutritionist to discuss the American Cancer Society nutrition guidelines in cancer survivorship; they will not be restricted to when they can eat. Participants in both groups will give us valuable information regarding how diet is related to the experience of fatigue. The purpose of this study is to test the effects of a 12-week TRE intervention vs. an unrestricted eating pattern on fatigue, the sustainability of the program at 24 weeks, and the effects of TRE on circadian rhythm and sugar metabolism. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/02/2025

Locations: University of Maryland, Baltimore, Baltimore, Maryland

Conditions: Neoplasms, Blood Cancer, Fatigue, Diet Habit, Survivorship, Fasting, Intermittent

Learn More ›

Sample Collection and Tracking for the Developmental Therapeutics Clinic

NCT03269578

Recruiting

Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

06/28/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Lymphoma

Learn More ›

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT00071045

Recruiting

This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases. The specimens may be used to evaluate the effectiveness of known therapies, refine treatment approaches, identify potential new therapies, and explore opportunities for disease prevention. The following individuals 2 years of age or older may be eligible for this study: * Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder who are being screened for or who are enrolled in a treatment study at the NIH Clinical Center * HLA-compatible donor family members (18 years of age or older) of the above patients who are being evaluated for or are enrolled in an NIH study as a stem cell transplant donor * Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder or a bone marrow failure condition who cannot participate in an NIH treatment protocol or travel to the NIH Clinical Center and who are referred for participation through their home health care provider. Research samples will be collected from participants when blood is drawn or bone marrow, urine, or stool is collected, or tumor or other tissue is biopsied as part of their general medical care. Investigators may periodically request an additional sample of blood, stool, or urine. Participants who are 18 years of age or older may donate a large number of white blood cells through a procedure called leukapheresis. This procedure is not part of general medical care and would be done for research purposes only. For apheresis, a catheter (plastic tube) is placed in a vein in the subject's arm. Blood flows from the vein into a cell separator machine, where the white cells are separated from the red cells, platelets, and plasma by a spinning process. The white cells are removed and collected, and the rest of the blood is returned to the subject through a second tube placed in the other arm. ... Read Less

Gender:

ALL

Ages:

Between 2 years and 100 years

Trial Updated:

06/26/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Neoplasms, Hematologic Neoplasms, Healthy Volunteers

Learn More ›

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796

Recruiting

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Gender:

ALL

Ages:

All

Trial Updated:

06/24/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +181 locations

University of Alabama Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Arizona Cancer Center, Scottsdale, Arizona

Local Institution - 01021, Tucson, Arizona

City Of Hope, Duarte, California

University Of California San Diego Moores Cancer Center, La Jolla, California

Local Institution - 01206, Los Angeles, California

Local Institution - 01043, Sacramento, California

University of California, San Francisco- California, San Francisco, California

UCLA Medical Centre-Santa Monica, Santa Monica, California

Stanford Cancer Center, Stanford, California

University Of Colorado Cancer Center, Aurora, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Local Institution - 01050, Washington, District of Columbia

The Mayo Clinic - Jacksonville, Davis-E, Jacksonville, Florida

Baptist Cancer Center, Miami, Florida

Local Institution - 01035, Orlando, Florida

H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

Northside Hospital, Inc, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

University Of Chicago Medical Center, Chicago, Illinois

Local Institution - 01040, Maywood, Illinois

Local Institution - 01063, Niles, Illinois

IN Univ Simon Cancer Center, Indianapolis, Indiana

Local Institution - 01020, Indianapolis, Indiana

Kansas University Medical Center, Westwood, Kansas

Cancer Center of Kansas, Wichita, Kansas

University Of Kentucky, Lexington, Kentucky

Norton Cancer Institute Louisville Oncology, Louisville, Kentucky

Local Institution - 01026, New Orleans, Louisiana

University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Sidney Kimmel Comp Cancer Center at Johns Hopkins, Baltimore, Maryland

National Cancer Institute, Bethesda, Maryland

Local Institution - 01107, Boston, Massachusetts

Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts

Local Institution - 01106, Boston, Massachusetts

University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Karmanos Cancer Center Wayne State University, Detroit, Michigan

Providence Cancer Institute, Southfield, Michigan

M Health Fairview University of Minnesota Medical Center - East Bank, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 01030, East Brunswick, New Jersey

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Memorial Hosp, Morristown, New Jersey

Local Institution - 01053, New Brunswick, New Jersey

New York Oncology Hematology P.C., Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

Local Institution - 01066, New York, New York

Weill Cornell Medicine / New York Presbyterian Hospital, New York, New York

Icahn School Of Medicine At Mount Sinai, New York, New York

Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Local Institution - 01051, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Novant Health, Salisbury, North Carolina

Oncology Hematology Care, Inc., Cincinnati, Ohio

University Hospitals of Cleveland, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Local Institution - 01074, Columbus, Ohio

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma

Willamette Valley Cancer Institute, Eugene, Oregon

Providence Portland Medical Center, Portland, Oregon

Oregon Health and Science University OHSU, Portland, Oregon

Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia, Pennsylvania

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

UPMC Cancer Pavillion, Pittsburgh, Pennsylvania

Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina

Local Institution - 01064, Sioux Falls, South Dakota

Sarah Cannon Research Inst, Nashville, Tennessee

Texas Oncology, Dallas, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

University of Texas- MD Anderson, Houston, Texas

Sam Clinical Research Center, San Antonio, Texas

Local Institution - 01033, Temple, Texas

Texas Oncology, P.A. - Tyler, Tyler, Texas

University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

Intermountain Healthcare - LDS Hospital, Salt Lake City, Utah

University Of Virginia Health System, Charlottesville, Virginia

Local Institution - 01045, Norfolk, Virginia

Local Institution - 01023, Richmond, Virginia

Swedish Cancer Institute, Seattle, Washington

Local Institution - 01060, Seattle, Washington

Fred Hutchinson Cancer Center, Seattle, Washington

Local Institution - 01055, Tacoma, Washington

University Of Wisconsin, Madison, Wisconsin

Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin

Local Institution - 01069, Wauwatosa, Wisconsin

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Not set

Jules Bordet Institut, Anderlecht, Not set

Universitair Ziekenhuis Brussel, Brussel, Not set

Local Institution - 05200, Gent, Not set

Uz Gent, Gent, Not set

University Hospital Leuven, Leuven, Not set

Local Institution - UNK 2, Leuven, Not set

University Of Calgary, Calgary, Alberta

Local Institution - 02802, Vancouver, British Columbia

Local Institution - 02801, Hamilton, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

CIUSSS de l'Est-de-l'Ile-de-Montreal, Montreal, Quebec

Helsinki University Central Hospital (HUCH), Helsinki, Not set

Hopital Henri Mondor, Creteil-Paris, Not set

CHRU de Lille France, Lille Cedex, Not set

Local Institution - 09601, Lyon, Not set

Local Institution - 09400, Marseille Cedex 9, Not set

Local Institution - 09602, Marseille Cedex 9, Not set

CHU Montpellier - Hôpital Saint Eloi, Montpellier CEDEX 5, Not set

Chu Hotel Dieu, Nantes Cedex 01, Not set

Hopital Saint Louis, Paris, Not set

Hospital Saint Louis, Paris, Not set

Local Institution - 09600, Paris, Not set

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hopital Haut-Leveque, Pessac, Not set

Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, Not set

CHU La Miletrie, Poitiers Cedex, Not set

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse CEDEX 9, Not set

Gustave Roussy, Villejuif, Not set

Robert-Rossle-Klinik im HELIOS Klinikum Berlin-Buch Klinik fur Hamatologie, Onkologie u. Tumorimmuno, Berlin, Not set

Local Institution - 03155, Berlin, Not set

Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Not set

Local Institution - 03513, Dusseldorf, Not set

Local Institution - 03500, Frankfurt, Not set

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Kinikum der Universitaeat zu Koeln, Koeln, Not set

Local Institution - 03454, Muenster, Not set

LMU Klinikum der Universität, München, Not set

Local Institution - 03503, Tuebingen, Not set

University Hospital of Ulm, Ulm, Not set

Universitatsklinikum Wurzburg Medizinische Klinik und Poliklinik II, Würzburg, Not set

Ospedali Riuniti di Ancona, Ancona, Not set

Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Not set

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Naples, Not set

Local Institution - 07500, Roma, Not set

Ospedale Pediatrico Bambino Gesu, Rome, Not set

Istituto Clinico Humanitas, Rozzano (MI), Not set

Local Institution - 07610, Torino, Not set

Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Not set

Hokkaido University Hospital, Sapporo-shi, Hokkaido

National Cancer Center Hospital, Chuo-ku, Tokyo

Toranomon Hospital, Minato-ku, Tokyo

Local Institution - 13202, Bunkyo-ku, Not set

Kyushu University Hospital, Fukuoka, Not set

Tokai University Hospital, Isehara City, Kanagawa, Not set

Nagoya City University Hospital, Nagoya, Not set

Osaka Metropolitan university Hospital, Osaka, Not set

Japan Red Cross Medical Center, Shibuya-ku, Not set

Jichi Medical University Hospital, Shimotsuke, Not set

Local Institution - 13804, Shinjuku City, Not set

Local Institution - 04650, Amsterdam, Not set

Erasmus Medical Center - Daniel den Hoed, Rotterdam, Not set

Local Institution - 04400, Utrecht, Not set

Oslo Universitetssykehus, Oslo, Not set

Institutul Clinic Fundeni, Bucuresti, Not set

Hospital Universitario Vall D hebron, Barcelona, Not set

Hospital Universitari Germans Trias i Pujol ICO Badalona, Barcelona, Not set

Institut Clinic de Nefrologia i Urologia - Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital San Joan de Deu Barcelona, Esplugues de Llobregat, Not set

Hospital Infantil Universitario Nino Jesus, Madrid, Not set

Hospital 12 De Octubre, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Virgen Del Rocio, Sevilla, Not set

Karolinska University Hospital Huddinge, Stockholm, Not set

Inselspital Bern, Bern, Not set

Local Institution - 10850, Leeds, Not set

Kings College Hospital, London, Not set

UCL Cancer Institute, London, Not set

Christie Hospital Nhs Trust, Manchester Withington, Not set

Somers Cancer Research Building, Shirley Southampton, Not set

Conditions: Neoplasms

Learn More ›

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933

Recruiting

This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas

Gender:

ALL

Ages:

Between 3 years and 21 years

Trial Updated:

06/23/2025

Locations: Holly Lindsay MD, Aurora, Colorado +4 locations

Conditions: Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma

Learn More ›

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

NCT06431594

Recruiting

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: GSK Investigational Site, Lake Mary, Florida +46 locations

GSK Investigational Site, Lake Mary, Florida

GSK Investigational Site, Fairway, Kansas

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Grand Rapids, Michigan

GSK Investigational Site, Nashville, Tennessee

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, West Valley City, Utah

GSK Investigational Site, Cipoletti Rio Negro, Not set

GSK Investigational Site, Ciudad de Buenos Aires, Not set

GSK Investigational Site, Rosario, Not set

GSK Investigational Site, Blacktown, New South Wales

GSK Investigational Site, Macquarie University, New South Wales

GSK Investigational Site, Leuven, Not set

GSK Investigational Site, Ottawa, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Helsinki, Not set

GSK Investigational Site, Tampere, Not set

GSK Investigational Site, Lyon Cedex 08, Not set

GSK Investigational Site, Saint Herblain, Not set

GSK Investigational Site, Villejuif cedex, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Rozzano MI, Not set

GSK Investigational Site, Saitama, Not set

GSK Investigational Site, Shizuoka, Not set

GSK Investigational Site, Tokyo, Not set

GSK Investigational Site, Gyeonggi-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Amsterdam, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, COrdoba, Not set

GSK Investigational Site, Girona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Pozuelo De AlarcOn Madr, Not set

GSK Investigational Site, Stockholm, Not set

GSK Investigational Site, Uppsala, Not set

GSK Investigational Site, Cambridge, Not set

GSK Investigational Site, London, Not set

Conditions: Solid Tumors, Neoplasms

Learn More ›

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797

Recruiting

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2025

Locations: UAMS, Little Rock, Arkansas +107 locations

UAMS, Little Rock, Arkansas

University of California San Diego (UCSD) - Moores Cancer Center(All), La Jolla, California

Cedars-Sinai Medical Center, Los Angeles, California

Pasadena Liver Center, Pasadena, California

California Pacific Medical Center, San Francisco, California

UCLA University of California - Los Angeles, Santa Monica, California

John Muir Clinical Research, Walnut Creek, California

University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado

Uni. Of Miami- Sylvester Cancer Centre, Miami, Florida

Florida Cancer Specialists - South, Sarasota, Florida

Florida Cancer Specialists - East, West Palm Beach, Florida

Women's Cancer Care - Covington, LA, Covington, Louisiana

University Of Mississippi Medical Center, Jackson, Mississippi

Kansas City Research Institute, Kansas City, Missouri

Montefiore Medical Center (MMC) - Jack D. Weiler Hospital, Bronx, New York

Perlmutter Cancer Center- NYU Langone Health, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

MetroHealth Medical Center, Cleveland, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

University of Oklahoma Health Science Center, Oklahoma City, Oklahoma

Medical University of South Carolina, Charleston, South Carolina

Sanford Cancer Centre, Sioux Falls, South Dakota

Tennessee Oncology, Nashville, Tennessee

Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville, Nashville, Tennessee

Mary Crowley Cancer Research, Dallas, Texas

University of Texas Southwestern Medical, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson/University of Washington Cancer Consortium, Seattle, Washington

Sunnybrook Hospital, Toronto, Ontario

CHUM, Unit for Innovative Therapies, Montreal, Quebec

McGill University Health Centre, Montreal, Quebec

Beijing Cancer Hospital, Beijing, Not set

Peking Union Medical College Hospital, Beijing, Not set

Bethune Hospital of Jilin University, Changchun, Not set

Fujian Provincial Cancer Hospital, Fuzhou, Not set

Sun Yan-sen University Cancer Center, Guangzhou, Not set

Sun Yat-Sen Memrial Hospital, Sun Yat-Sen University, Guangzhou, Not set

Cancer Hospital of Shandong First Medical University, Jinan, Not set

Yunnan Cancer Hospital, Kunming, Not set

Fudan University Cancer Center, Shanghai, Not set

The Tenth People's Hospital; Shanghai Tongji University, Shanghai, Not set

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Not set

Tianjin Cancer Hospital, Tianjin, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

Odense University Hospital, Odense, Not set

CHU Amiens-Picardie (Hopital Sud), Amiens, Not set

CHU Bordeaux, Bordeaux, Not set

CHU Cavale Blanche, Brest, Not set

Centre François Baclesse, Caen, Not set

Centre Jean Perrin, Clermont-Ferrand, Not set

Hôpital Beaujon, Clichy, Not set

Centre Georges-François Leclerc, Dijon, Not set

Grenoble University Hospital (Centre Hospitalier Universitaire Grenoble Alpes), La Tronche, Not set

CHU de LILLE - Hôpital HURIEZ, Lille, Not set

Hepatology, Hopital de la Croix-Rousse - 103 grande rue de la Croix-Rousse, Lyon, Not set

Centre Léon Bérard, Lyon, Not set

Institut Paoli-Calmettes, Marseille, Not set

Centre Antoine Lacassagne, Nice, Not set

Institut Curie - Centre de Recherche, Paris, Not set

APHP Hospital Saint-Antoine, Paris, Not set

AP-HP Université de Paris, Port Royal, Paris, Not set

Hopital Europeen Georges-Pompidou (HEGP), Paris, Not set

Hopital de la Croix Saint-Simon, Paris, Not set

Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)(Hopitaux de Bordeaux) - Groupe hospitalier Sud - Hopital Haut-Levequ, Pessac, Not set

Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, Not set

Insitute de Cancérologie de l'Ouest - Centre René Gauducheau, Saint-Herblain, Not set

ICANs, Strasbourg, Not set

Gustave Roussy Institute (IGR), Villejuif, Not set

Clinica Oncologica AOU (Azienda Ospedaliero Universitaria) delle Marche, Ancona, Not set

Istituto Clinico Humanitas, Rozzano, Milan, Not set

Fondazione Policlinico Gemelli IRCCS, Rome, Not set

Eisai Trial Site #5, Nagoya, Aichi

Eisai Trial Site #11, Toyoake, Aichi

Eisai Trial Site #2, Kashiwa, Chiba

Eisai Trial Site #8, Matsuyama, Ehime

Eisai Trial Site #7, Kurume, Fukuoka

Eisai site #13, Akashi, Hyogo

Eisai Trial Site #10, Kawasaki, Kanagawa

Eisai Trial Site #12, Kamigyo-ku, Kyoto

Eisai Trial Site #3, Osakasayama, Osaka

Eisai Trial Site #9, Hidaka, Saitama

Eisai Trial Site #1, Chuo-Ku, Tokyo

Eisai Trial Site #6, Koto-ku, Tokyo

Eisai Site 15, Minato-ku, Tokyo

Eisai Trial Site #4, Chiba, Not set

Eisai site #14, Niigata, Not set

Eisai Trial Site #1, Seongnamsi Bundang, Gyeonggi-Do

National Cancer Center, Goyang-si Gyeonggi-do, Ilsandong-gu

Korea University Guro Hospital, Guro-gu, Seoul

Eisai Trial Site #5, Jongno-gu, Seoul

Seoul National University Hospital, Jongno-gu, Seoul

Seoul St. Mary's Hospital, Seocho-Gu, Seoul

Eisai Trial Site #2, Seodaemun, Seoul

Asan Medical Centre, Songpa-Gu, Seoul

Eisai Trial Site #4, Songpa-gu, Seoul

Eisai Trial Site #3, Seoul, Not set

H. Clinico San Carlos, San Carlos, Madrid

Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO), Barcelona, Not set

University Hospital A Coruña, Coruna, Not set

Hospital Universitario de Jaén, Jaen, Not set

Clínica Universidad de Navarra, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Chang Gung Medical Foundation - Kaohsiung Branch, Kao-Hsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Chang Gung Medical Foundation - Linkou Branch, Taoyuan, Not set

Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Learn More ›

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

NCT06077877

Recruiting

The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/03/2025

Locations: GSK Investigational Site, San Francisco, California +8 locations

Conditions: Neoplasms

Learn More ›

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NCT04192344

Recruiting

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/20/2025

Locations: Precision NextGen Oncology, Beverly Hills, California +16 locations

Conditions: Neoplasms, Tenosynovial Giant Cell Tumor

Learn More ›

13 - 24 of 58